CCAAT/enhancer-binding protein delta (CEBPD) is associated with the regulation of apoptosis and cell proliferation and is a candidate tumor suppressor gene. Here, we investigated its role in hepatocellular carcinoma (HCC). We observe that CEBPD mRNA expression is significantly downregulated in HCC tumors as compared with adjacent tissues. Protein levels of CEBPD are also lower in tumors relative to adjacent tissues. Reduced expression of CEBPD in the tumor correlates with worse clinical outcome. In both Huh7 and HepG2 cells, shRNA-mediated CEBPD knockdown significantly reduces cell proliferation, single cell colony formation and arrests cells in the G 0 /G 1 phase. Subcutaneous xenografting of Huh7 in nude mice show that CEBPD knockdown results in smaller tumors. Gene expression analysis shows that CEBPD modulates interleukin-1 signaling. We conclude that CEBPD expression uncouples cancer compartment expansion and clinical outcome in HCC, potentially by modulating interleukin-1 signaling. Thus, although our results support the notion that CEBPD acts as a tumor suppressor in HCC, its action does not involve impairing compartment expansion per se but more likely acts through improving anticancer immunity.
Introduction
Cancerous disease is characterized by abnormal cell growth with the potential to invade or spread to other parts of the body (1) . As it ultimately involves the withdrawal of physiological antiexpansionary control from the cancer cells, suppression of expansion of the cancer cell compartment size is the mainstay of current preclinical research. To this end, novel anticancer strategies are explored by measuring cell proliferation and death in cell cultures and by visualizing tumor expansion in experimental rodents, most often in xenograft models. Although this approach has been proven successful in forming the conceptual basis for novel therapy in many forms of cancers, it is fair to say that this approach has proven disappointing for a range of therapy-resistant oncological manifestations, suggesting that these cancer models only partially capture disease dynamics in humans (2) . Nevertheless, the notion that cancer compartment expansion constitutes the most relevant parameter in therapydirected oncological research remains largely unchallenged. This is especially the case for those tumor types that are refractory to current therapies and thus are clinically only subject to palliative therapy (3) .
An important cancer type in this regard is hepatocellular carcinoma (HCC). HCC is the fourth cause of cancer-related death worldwide (4, 5) . The disease is unusually resistant to therapies other as surgery and thus is associated with very high fatality (6) , especially in metastatic disease. The latter is depressingly common as early symptoms are inconspicuous, and disease only becomes manifest at advanced stages. With >0.5 million new cases arising every year, the quest for devising a novel therapy for the treatment of HCC is one of utmost urgency (7) . Numerous studies have been directed at understanding the molecular processes driving HCC cell proliferation and to develop strategies aimed at inhibiting this proliferation. These studies, however, have yet largely failed to establish strategies that counteract clinical HCC, raising questions as to the extent to which the experimental models used reflect human disease faithfully.
An important consideration to take into account in this respect is the influence and to a certain extent also the species-specific actions of the tumor stroma (8) . Although HCC xenografts in mice are supported by murine-derived stromal structures, we observed earlier that co-grafting human HCC with human mesenchymal cells substantially promotes HCC progression (9) . It is thus possible that the incomplete HCC-stromal interaction in preclinical models, as a consequence of defective species compatibility, results in the loss of important aspects of the regulation of the HCC tumor expansion process. In vitro modeling often does not involve stromal-cancer cell interactions at all. Thus, it could be shown that biological effects in HCC have alternative consequences in oftenused preclinical models of disease and in clinical practice.
This consideration prompted us to explore both the clinical and preclinical importance of CCAAT/enhancer-binding protein delta (CEBPD), which appears involved in oncological processes in general through modulating stroma-cancer cell interaction. CEBPD is recognized as an inflammatory response factor and plays a critical role in activating the innate immune response (10) . CEBPD is a bZIP transcription factor that belongs to the CEBPD family, which members exert their action through forming homodimers and heterodimers and subsequent binding to specific DNA regulatory sequences, especially in the control of target gene expression (11, 12) and regulation of proliferation (13) , cell cycle, apoptosis, metastasis and inflammation cytokine signaling (14) following appropriate extracellular cues. On one hand, CEBPD expression is closely linked to the cancer tumorigenesis, whereas, on the other hand, its action appears highly context dependent. CEBPD seems, therefore, a candidate gene for testing whether preclinical compartment expansion and clinical effects can be uncoupled in relation to HCC.
Our results demonstrate that CEBPD has a dualistic role in HCC. Its expression appears protective in HCC patients, but in preclinical models, it supports the HCC process. Our results thus show that CEBPD uncouples preclinical models of HCC with clinical disease. The apparent lack of correlation suggests that current preclinical models do not fully capture HCC, and this may explain the failure of such models to identify novel treatment approaches.
Materials and methods

Cell culture
Monthly short tandem repeat identity-verified (verification commercially performed by the molecular pathology department of the Erasmus MC) and American Type Culture Collection (ATCC, Manassas, VA)-obtained mycoplasma-free (monthly commercially checked by GATC Biotech, Konstanz, Germany) human HCC cell lines were maintained as described previously (15) . In brief, HEK29, Hep3B, Huh6, Huh7, PLC/PRF/5, SNU182, SNU398 and SNU449 were cultured in Dulbecco's modified Eagle's medium (Lonza, Breda, The Netherlands) supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 1% penicillin/streptomycin (Gibco, Bleiswijk, The Netherlands). HepG2 cells were cultured on fibronectin/collagen/albumin-coated plates (AthenaES) in Williams E medium (Invitrogen-Gibco, Breda, The Netherlands) complemented with 10% (v/v) fetal calf serum, 100 IU/ml penicillin, 100 μg/ml streptomycin and 2 mM l-glutamine. The human liver organoids were cultured as described previously (16) . Cell lines were routinely confirmed to be mycoplasma free using the LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich). Cell counting process was performed by using Countess™ II Automated Cell Counter (Thermo Fisher Scientific).
Tissue microarray (TMA) and TCGA dataset
Archived formalin-fixed paraffin-embedded tissue samples from 154 patients who underwent hepatic resection for HCC at Erasmus MC-University Medical Center (EMC, n = 94) or Amsterdam Medical Center (AMC, n = 60) between June 2001 and July 2014, were used for this study. Clinical data of this HCC cohort have been published previously (17) . For TMA slides, three or four 0.6 mm cores had been obtained from the tumorous area of 141 HCC patients, and two 0.6 mm cores had been obtained from the paired tumorfree liver (TFL) area of 133 of these patients. Vital tumor areas and TFL tissue were identified by experienced gastrointestinal pathologists using earlier archived hematoxylin-stained slides. The TMAs were constructed employing an automated tissue-arrayer (ATA-27). The use of patient materials was approved by the medical ethical committee of Erasmus MC (Medisch Ethische Toetsings Commissie Erasmus MC). Immunohistochemical scoring was conducted by two independent investigators (P.L. and K.C.) blinded to clinical outcome and differences resolved by mutual agreement. In tumor tissues, stained nuclei of tumor cells were scored and in TFL stained hepatocyte nuclei. Percentages of stained nuclei were scored as 1 (<25%), 2 (25-70%) or 3 (>70%). In addition, the intensity of staining was defined from zero to three. Expression level was calculated by multiplication of intensity score and percentage score, resulting in levels ranging from 0 to 9.
TCGA LIHC RNA-Seq (level 3) and corresponding clinical data were downloaded from (https://tcgadata.nci.nih.gov/tcga/). There are 371 patient's tumor samples and corresponding 50 paired adjacent tumor-free tissues in this publically available dataset.
Lentiviral-shRNA packaging and infection
Hek293 cells were transfected with packaging plasmids and pLKO.1-based shRNA lentiviral vectors (Biomics Center in Erasmus Medical Center) targeting CEBPD; a scrambled control vector (shCTR) was also used. After 3 days infection, HepG2 and Huh7 cells were subjected to selection by puromycin (3 μg/ml); shRNA sequences are listed in the Supplementary  Table S1, available 
Western blot analysis
Western blot analysis has been extensively described elsewhere (18) . In short, protein samples were collected in a Laemmli sample buffer with 0.1 M DTT and subsequently heated for 5 min at 95°C. Protein lysates were then subjected to polyacrylamide gel electrophoresis on a 8-15% sodium dodecyl sulfate gel for protein size-based separation by electrophoresis. All the primary antibodies against CEBPD (sc-636), β-actin (sc-47778) (at a final dilution of 1:1000, Supplementary Table S2, available at Carcinogenesis Online) were incubated with the membranes at 4°C for an overnight period. Next, 1 h with an IRDye-conjugated secondary antibody (1:5000 anti-rabbit or 1:10000 anti-mouse dilution) at room temperature. Protein intensity was detected with the Odyssey 3.0 Infrared Imaging System.
Quantitative real-time PCR
A Machery-NucleoSpin RNA II kit (Bioke, Leiden, The Netherlands) was used for RNA isolation. The reverse transcription to produce cDNA was
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performed using a Takara cDNA Synthesis Kit with random primers (Takara Bio, Shiga, Japan). Quantification of gene expression in HCC cell lines was quantified using SYBR-Green-based (Applied Biosystems® SYBR® Green PCR Master Mix) real-time PCR on the StepOnePlus™ System (Thermo Fisher Scientific Life Sciences). GAPDH was used as a housekeeping gene, and expression level of target genes was normalized to GAPDH by the 2 −ΔΔCT method. Primers sequences involved in this study were listed in Supplementary Table S2 , available at Carcinogenesis Online.
Cell proliferation and colony formation assay
Cell proliferation was measured essentially similar as described earlier (19) . In short, CEBPD stable knockdown cells and scrambled sequence control cells were seeded in a 96-well microtiter plate with 6 replicate wells. Measurements were taken from days 1 to 7, with an interval of 2 days. For measurements, 10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) was added to each well. After 3 h of incubation at 37°C under a 5% CO 2 atmosphere, the medium was completely removed and replaced by 100 μl dimethyl sulfoxide which dissolves reaction products that indicate cell viability. The absorbance of each well will be measured at absorbance 490 nm by a microplate absorbance reader (BIO-RAD).
For colony formation, cells were harvested and resuspended in culture medium. A total of 1000 cells were seeded in 6-well tissue culture plates, with 3 independent wells for each experimental condition. After 14 days, the medium was thoroughly removed followed by two times of washing with phosphate-buffered saline, and the addition of a 0.5% crystal violet solution was then used for 15 min to stain cells. The number of colonies that contained >20 cells was analyzed and counted by Image J.
Cell-cycle analysis by propidium iodide
5 × 10 5 cells were seeded in 6-well plates and harvested when a confluence of ~80% was reached. Cells were washed two times with phosphatebuffered saline and fixed in ice-cold 70% ethanol. Cells were pelleted by centrifugation at 2000 rpm for 5 min, followed by 2 washes in phosphatebuffered saline. The resulting pellets were subsequently stained employing 50 mg/ml propidium iodide and 0.1 mg/ml RNase for 30 min at room temperature and then subjected to flow cytometric analysis. Cell-cycle status was analyzed by FlowJo_V10 software.
In vivo HCC xenograft study in nude mice
HCC xenograft models were established by subcutaneous transplantation of Huh7 cells into nude mice (2.5 × 1 0 6 cells per mouse; n = 11 mice per group). CEBPD knockdown cells and corresponding control cells were injected into the lower left or right flank of the same mice, respectively. After 4 weeks, mice were killed, and tumors were immediately removed and analyzed. All animal experiments were approved by the Committee on the Ethics of Animal Experiments of the Erasmus Medical Center.
Statistical analysis
Protein and mRNA expression of CEBPD between the HCC tumor tissues and normal adjacent tissues were compared using the paired Student's t-test and the Mann-Whitney test. For all the functional studies, potential differences between the experimental groups were analyzed using a paired Student's t-test. P < 0.05 (indicated in the figures as single asterisk) was considered statistically significant. P < 0.01 (indicated in the double asterisks) and P < 0.001 (triple asterisks) were regarded as highly significant. All statistical analyses were performed in GraphPad Prism 5.
Results
Downregulation of CEBPD mRNA in HCC tumors and its clinical significance
As a first analysis of the potential clinical significance of CEBPD in HCC, we exploited the TGCA resource that allows analysis of transcript levels in cancers and adjacent tissues. We identified data on CEBPD transcript levels in primary HCC of 371 patients, and for 50 of those also, data on adjacent TFL tissue are available. An overall analysis of transcript levels in all HCC and adjacent tissues showed that CEBPD mRNA levels are significantly lower in tumor as compared with adjacent TFL tissue (P < 0.0001, Figure 1A) , and a paired analysis of the 50 cases in which data from both TFL tissue as well as HCC are present of the same patients made this point even more clear (P < 0.0001, Figure 1B ). We aimed to correlate the CEBPD expression data to clinical descriptors such as gender, age, a history of viral hepatitis and pathology grade, but no relationships emerged.
However, we observe a link between CEBPD expression and tumor progression as assessed by American Joint Committee on Cancer (AJCC) staging (20) . We found that higher staging is associated with significantly lower CEBPD mRNA expression in tumors ( Figure 1C) . Thus, clinical progression of HCC is strongly associated with lower CEBPD mRNA levels. Next, we investigated the relationship between CEBPD mRNA expression and patients' overall survival in the TCGA LIHC cohort by KaplanMeier test. When comparing the 20% patients with the highest CEBPD mRNA tumor expression with the 20% patients with the lowest tumor expression, we found that low CEBPD mRNA expression was associated with poorer survival (P = 0.043, logrank test; Figure 1D ).
Downregulation of CEBPD protein expression in HCC tumors and tumor cell lines
To confirm that the observed downregulation of CEBPD transcripts in HCC as detected in our analysis of the TGCA resource corresponds to lower protein levels of CEBPD in HCC tumor cells (and does not derive from e.g. stromal cells), we analyzed TMAs of tumors of 154 HCC patients resected at Erasmus MC or AMC and paired TFL tissues from 133 of these patients. We observed that lower levels of tumor cell-specific CEBPD protein expression in HCC tissues as compared with adjacent paired TFL tissues (P < 0.0001, Figure 1E ). In apparent agreement, when we used qRT-PCR and western blot to examine the CEBPD mRNA levels and protein levels in nine often-used HCC cell lines and compared results to healthy human liver organoids, we observed that compared with healthy liver tissue, the expression of CEBPD is markedly reduced in all the HCC cell lines (Figure 2A and B). We concluded that CEBPD downregulation is an intrinsic property of the HCC process and initiated investigations as to test whether preclinical models of HCC capture this aspect of liver cancer.
Paradoxal reduction of cell proliferation and colony formation following knockdown of CEBPD in HCC cell lines
To investigate whether the clinical relevance of CEBPD downregulation in HCC is mirrored by increased aggressiveness in in vitro models of HCC, we constructed CEBPD knockdown derivatives of both Huh7 and HepG2 employing an RNAi-mediated approach. This approach was successful in that various clones with reduced levels of CEBPD were created (henceforth referred to as CEBP-KD cells), especially when compared with cells transfected with a scrambled control vector (shCTR cells; Figure 3) . Subsequently, the resulting clones were interrogated for overall proliferation, their capacity for single cell-derived colony formation as well as the effects of loss of CEBPD on cell cycling. We observed that CEBPD-KD cells are substantially hampered with respect to proliferative and colony-forming potential ( Figure 4A and B). We also investigated the effects of loss of CEBPD expression on cell cycling in these preclinical models of HCC, employing propidium iodide staining and fluorescence-activated cell sorting analysis. We found that CEBPD-KD cells display G 0 /G 1 cell-cycle arrest ( Figure 4C ). In conjunction, these results reveal a paradoxical inhibition of apparent pro-oncogenic behavior in CEBPD-KD cells, which contrasts the loss of CEBPD expression in clinical HCC and suggests that these in vitro models fail to capture important aspects of the HCC process.
Stable lentiviral-mediated knockdown of CEBPD in HCC cell lines impairs tumorigenesis in vivo
The notion that the clinical effects of downregulation of CEBPD expression in clinical HCC are not reflected in current preclinical models of disease is substantiated in experiments in which we used nude mouse xenografting to examine the tumorigenicity of (2) or strong (3) and for percentages of positive nuclei (<25% = 1, 25-70% = 2, >70% = 3). *P < 0.05; ***P < 0.001; ****P < 0.0001.
shRNA-mediated CEBPD-KD cell lines. At bay with the observed negative relationship between CEBPD downregulation and the clinical outcome of HCC, we observed that CEBPD-KD cells form much smaller tumors in mice as compared with control cells (P < 0.05, Figure 5 ). Subsequently, we initiated experiments as to dissect the potential mechanistic basis of the observed discrepancy.
RNA-seq analysis of the effects of CEBPD target genes
To provide mechanistic clues as to the effect of CEBPD downregulation, we exploited the GEO RNA-seq resource. Under accession number GSE69604 (21) created based on a P-value cutoff of <0.05 and fold change of >1.5 or < −1.5, and we used IPA software to establish the signaling pathways affected by CEBPD-KD. Also as a consequence of a cutoff Z-score ≥2, only a single signal transduction category was considered relevant by IPA, in case 'acute phase response signaling' is mapped by IPA software, and includes 11 genes for each clone). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
( Figure 6A ). Although the background of the cell line in this IPA analysis is nonhepatic, the results may indicate that difference between the clinical and preclinical behavior of CEBPD expression maybe due to a role of CEBPD in supporting acute phase response signaling.
Confirmation of differential gene expression by qRT-PCR
A potential role for acute phase response signaling in explaining the differential effects between clinical HCC and preclinical models was supported by experiments in which the effects of CEBP-KD in Huh7 and HepG2 cell lines on the expression of the gene products involved in acute phase response signaling were determined using qRT-PCR. The results demonstrate that with the possible exception of Related RAS Viral Oncogene Homolog page (RRAS), the effects of CEBPD-KD mirror those seen in the GEO resource for MCF-7 cells ( Figure 6B ). Especially expression of IL1RN (interleukin 1 receptor antagonist), ITIH2 (inter-alphatrypsin inhibitor heavy chain 2) and SERPINA3 [serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3] are significantly reduced, up to 50% following CEBPD-KD. Conversely, the expression level of CRABP2 (cellular retinoic acid binding protein 2) was doubled. We also verified that the link between CEBPD and interleukin 1 receptor antagonist existed in the TCGA resource liver cancer dataset (Spearman scores were 0.31 and 0.39; Figure 6C ). Acute phase response signaling involves multiple cell types, and its importance may only emerge in the context of interaction of different types of cell that may not exist in in vitro cultures are may require species-specific signaling. Thus, the observation that acute phase response genes are a target of CEBPD provide a rational explanation for the difference between preclinical models and clinical HCC.
Discussion
In line with their recognized status as a relevant family of transcription factors, all five C/EBP family members have been associated with altered cellular fate, including cell-cycle arrest, differentiation (22) and apoptosis (23) . In this study, we observed that outcome of clinical HCC associates with reduced CEBPD expression. This fits with observations that in genetic murine models prone to develop mammary cancer, CEBPD appears to act as a tumor suppressor (24) , and the observations from the present study suggest a similar functionality of CEBPD with respect to clinical HCC as well. The failure of preclinical models to capture this effect appears to relate either the absence of interaction between different cell types for in vitro models or possibly hampered intracellular communication due to species differences in xenograft models. In support of this latter notion is also the apparent role of CEBPD in acute phase response signaling, but this line of thinking is fostered by literature data as well that show in glioblastoma CEBPD mRNA overexpression in mesenchymal cells in a manner related to adverse prognosis (25) . Nevertheless, a role of CEBPD as a tumor suppressor gene appears certainly not universal: for urothelial carcinoma; CEBPD copy number amplification and overexpression can be related to poor prognosis and promote tumor metastasis (26) . However, CEBPD mRNA expression downregulation had been found in many different tumor types, such as HCC (27) , leukemia (28), breast cancer (29), cervical cancer (30) , and it also can be a biomarker for predicting better survival in breast cancer patients (31) . Thus, the status of CEBPD as a candidate tumor suppressor gene is strong, and the present work adds to the current momentum in the field in this respect. The discrepancy between preclinical models and clinical HCC with regard to CEBPD probably relates to its function in inflammation (32) , which although relevant for clinical disease course is poorly captured in current models of disease. CEBPD is well established to become transcriptionally active in ongoing inflammatory reactions, and the current work shows that its downregulation is associated with loss of immunerelated signaling. It has become clear that the immune system is an important disease-constraining factor in HCC (33) , and one can envision that loss of CEBPB provokes an immune tolerant environment that enables cancer to thrive even in the presence of functional immunity. In support of this notion is our finding that CEBPD-KD leads to upregulation of CRABP, which is well known to stimulate regulatory lymphocytes and may thus foster immune escape of cancers. Preclinical models that involve overall proliferation or colony formation obviously do not measure immune system involvement. Likewise, xenografting cancer cells in immunodeficient mice also only minorly involves the immune system. Nevertheless, the effects on compartment expansion of CEBPD in HCC in the absence of immune interaction are quite strong, and the observation that CEBPD behaves in clinical HCC as tumor suppressor shows that the importance of immunological pressure in clinical HCC development is even larger as contemplated hitherto and emerges from the current studies the major force driving the HCC process. Disregarding the exact details as to the discrepancy in the effects of loss of CEBPD expression in clinical HCC versus the effect of CEBPD-KD in preclinical models, the present study has established that translation of findings obtained in often-used models of this disease like cell proliferation, single cell colony formation and xenografting is not straightforward and may actually be counterproductive. As these models continue to form the mainstay of current HCC research, this lack of translational capacity may be a reason why efforts to combat this disease have been so notably unsuccessful. Thus, we interpret the current study as a call re-evaluate current models and concentrate on those which do involve functional interaction with the immune system.
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